Literature DB >> 8513657

Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients.

J Grevel1, B K Post, B D Kahan.   

Abstract

Dosage adjustments of cyclosporine are confounded with an unexpected degree of variability, thus invalidating a direct proportionality between the oral dose rate and the steady-state concentration. In 1033 observations of dose rate and average steady-state concentration collected during therapeutic monitoring (area under the curve method) in 134 adult kidney transplant patients, a population pharmacokinetic analysis showed that a Michaelis-Menten model fitted the data better than a linear clearance model. It was further shown that the Michaelis-Menten constant (Km) parameter of the Michaelis-Menten model (the average steady-state concentration at half-maximal dose rate) increased during the first 4 months after transplantation whereas the maximal dose rate of the Michaelis-Menten model (Vmax) remained constant. The following parameters with interindividual variation in parenthesis were estimated: Vmax = 852 mg/24 hr (43%) and Km at 114 days after transplantation = 349 ng/ml (117%). An algorithm was derived from this population model that guides the clinician during the adjustment of oral cyclosporine dose rates.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513657     DOI: 10.1038/clpt.1993.86

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.

Authors:  Chen-Yan Zhao; Zheng Jiao; Jun-Jun Mao; Xiao-Yan Qiu
Journal:  Br J Clin Pharmacol       Date:  2016-02-26       Impact factor: 4.335

Review 2.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Simulation for population analysis of Michaelis-Menten elimination kinetics.

Authors:  Y Hashimoto; T Koue; Y Otsuki; M Yasuhara; R Hori; K Inui
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

4.  Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients.

Authors:  Bing Chen; WeiXia Zhang; ZhiDong Gu; Juan Li; YuXin Zhang; WeiMin Cai
Journal:  Eur J Clin Pharmacol       Date:  2010-12-16       Impact factor: 2.953

5.  A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.

Authors:  L Claret; A Iliadis; P Macheras
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

Review 6.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 7.  Population pharmacokinetics of cyclosporine in transplant recipients.

Authors:  Kelong Han; Venkateswaran C Pillai; Raman Venkataramanan
Journal:  AAPS J       Date:  2013-06-18       Impact factor: 4.009

8.  External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients.

Authors:  Jun-Jun Mao; Zheng Jiao; Hwi-Yeol Yun; Chen-Yan Zhao; Han-Chao Chen; Xiao-Yan Qiu; Ming-Kang Zhong
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335

9.  Change of Cyclosporine Absorption over the Time after Kidney Transplantation.

Authors:  Behzad Einollahi; Mojtaba Teimoori; Zohreh Rostami
Journal:  Nephrourol Mon       Date:  2012-03-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.